Latest news with #RNAP
Miami Herald
30-05-2025
- Business
- Miami Herald
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, is rescheduling its intra-quarter webcast and investor update call to June 17, 2025, from June 3, 2025, to allow for the implementation of a reverse stock split that will become effective on June 2, 2025. Prepared remarks by members of the Applied DNA management team will be followed by a live question-and-answer session with the Company's sell-side analysts and institutional investors. Webcast and Conference Call Date & Time: Tuesday, June 17 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll-free): 844-887-9402International callers: 412-317-6798Canadian callers (toll-free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll-free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll-free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences, Inc.
Miami Herald
14-05-2025
- Business
- Miami Herald
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. To align with its Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the Company will hold an intra-quarter investor update call on June 3, on which management will discuss the Company's strategic priorities. Webcast and Conference Call Date & Time: Tuesday, June 3 @ 4:30 p.m. Eastern Time Dial In: Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll free): 877-344-7529, replay access code 3446494Replay for international callers: 412-317-0088, replay access code 3446494Replay for Canadian callers (toll free): 855-669-9658, replay access code 3446494 An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the 'Company Presentations' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information:Investor Relations: Sanjay M. Hurry, 917-733-5573, ### SOURCE: Applied DNA Sciences
Associated Press
14-05-2025
- Business
- Associated Press
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ('Applied DNA' or the 'Company'), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website. To align with its Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the Company will hold an intra-quarter investor update call on June 3, on which management will discuss the Company's strategic priorities. Webcast and Conference Call Date & Time: Tuesday, June 3 @ 4:30 p.m. Eastern Time Dial In: A replay of the conference call will be available for 7 days following the conclusion of the call: An accompanying slide presentation will be embedded in the webcast (live and replay) that will also be accessible as a stand-alone document via the ' Company Presentations ' page of the Applied DNA investor relations website. The webcast replay of the call will be available approximately one hour after the end of the call on the ' Company Events ' page. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ('DNA'). Using the polymerase chain reaction ('PCR') to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ('RNAP') for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, [email protected] Web: ### SOURCE: Applied DNA Sciences press release
Yahoo
12-02-2025
- Business
- Yahoo
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m. ET on that same day. Webcast and Conference Call Date & Time: Thursday, February 13 @ 4:30 p.m. ET Dial In: Domestic callers (toll free): 844-887-9402 International callers: 412-317-6798 Canadian callers (toll free): 866-605-3852 Live webcast: A replay of the conference call will be available for 7 days following the conclusion of the call: Replay for domestic callers (toll free): 877-344-7529, replay access code 7896562 Replay for international callers: 412-317-0088, replay access code 7896562 Replay for Canadian callers (toll free): 855-669-9658, replace access code 7896562 An accompanying slide presentation will be embedded in the webcast (live and replay) that can also be accessed via the 'Company Presentations' page of the Applied DNA investor relations website ( The webcast replay of the call will be available approximately one hour after the end of the call on the 'Company Events' page ( About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. For additional information: Investor Relations: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
STONY BROOK, NY / / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@ The Special Meeting was originally held on January 23, 2025, but, due to a lack of quorum, was adjourned to allow additional time for the Company's stockholders to vote on Proposal One (the "Warrant Exercise Proposal") set forth in the Company's definitive proxy statement (the "Proxy Statement") filed with the U.S. Securities and Exchange Commission on December 10, 2024: to approve, in accordance with Nasdaq Listing Rule 5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October 30, 2024. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we currently operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. YOUR VOTE IS IMPORTANT! Your vote is important, and we ask that you please vote "FOR" the Warrant Exercise Proposal. For specific instructions on how to vote your shares, please refer to the instructions on the Notice of Internet Availability of Proxy Materials you received in the mail, the section entitled "About the Special Meeting" beginning on page 1 of the Proxy Statement or, if you request to receive printed proxy materials, your enclosed proxy card. Please note that shares held beneficially in street name may be voted by you in person at the Special Meeting only if you obtain a legal proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares. If you have any questions or require any assistance with voting your shares, please call the Company's proxy solicitor, Kingsdale Advisors, at: 1- 855-682-9644 (toll free) or 1-646-491-9095 (call or text outside North America) or by email at contactus@ Additional Information In connection with the Company's Special Meeting, the Company has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to the shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. A copy of our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, including financial statements and any financial statement schedules required to be filed in accordance with SEC rules, will be sent without charge to any stockholder of the Company requesting it in writing from: Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Beth Jantzen. We also make available, free of charge on our website, all of our filings that are publicly filed on the SEC's EDGAR website, including Forms 10-K, 10-Q and 8-K, at Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: X: @APDN SOURCE: Applied DNA Sciences, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
